Stromberg K, Johnson G R, O'Connor D M, Sorensen C M, Gullick W J, Kannan B
Laboratory of Cell Biology, Food and Drug Administration, Bethesda, Maryland 20892.
Int J Gynecol Pathol. 1994 Oct;13(4):342-7. doi: 10.1097/00004347-199410000-00008.
Primary and metastatic ovarian cystadenocarcinomas, carcinomas of low malignant potential (borderline tumors), benign ovarian cystadenomas, and normal ovaries were compared for immunoperoxidase detection of the ligands epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha), amphiregulin (AR), cripto, and the receptors, epidermal growth factor receptor (EGF-R), and c-erbB-2. This matrix analysis of these EGF family members indicated no specific pattern of ligand or receptor expression with a specific ovarian histologic category except in the case of AR and TGF-alpha. AR was detected almost exclusively in borderline tumors, suggesting that these tumors may not arise as a pathological continuum between benign cystadenomas and invasive cystadenocarcinomas. Second, the presence of TGF-alpha immunoreactivity in the absence of coexpression of cripto or EGF appeared to be associated only with adenocarcinomas of high grade and stage.
对原发性和转移性卵巢囊腺癌、低恶性潜能癌（交界性肿瘤）、良性卵巢囊腺瘤及正常卵巢进行免疫过氧化物酶检测，以检测表皮生长因子（EGF）、转化生长因子-α（TGF-α）、双调蛋白（AR）、cripto等配体以及表皮生长因子受体（EGF-R）和c-erbB-2受体。对这些EGF家族成员的矩阵分析表明，除AR和TGF-α外，特定卵巢组织学类型与配体或受体表达无特定模式。AR几乎仅在交界性肿瘤中检测到，提示这些肿瘤可能并非起源于良性囊腺瘤和浸润性囊腺癌之间的病理连续过程。其次，在不伴有cripto或EGF共表达的情况下，TGF-α免疫反应性的存在似乎仅与高级别和晚期腺癌相关。
